Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

In this randomized noninferiority trial involving patients with rheumatoid arthritis, cardiovascular events and cancers occurred more frequently with tofacitinib than with a TNF inhibitor, and noninferiority of tofacitinib with respect to these end points was not established.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-01, Vol.386 (4), p.316-326
Hauptverfasser:	Ytterberg, Steven R, Bhatt, Deepak L, Mikuls, Ted R, Koch, Gary G, Fleischmann, Roy, Rivas, Jose L, Germino, Rebecca, Menon, Sujatha, Sun, Yanhui, Wang, Cunshan, Shapiro, Andrea B, Kanik, Keith S, Connell, Carol A
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Cancer therapies Cardiology Cardiology General Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - chemically induced Cardiovascular Diseases - epidemiology Confidence intervals Drug dosages FDA approval Female Health surveillance Heart Disease Risk Factors Hematology Herpes zoster Humans Incidence Janus Kinase Inhibitors - administration & dosage Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - therapeutic use Male Methotrexate Middle Aged Neoplasms - chemically induced Neoplasms - epidemiology Oncology Oncology General Patients Piperidines - administration & dosage Piperidines - adverse effects Piperidines - therapeutic use Pulmonary embolisms Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Rheumatoid Arthritis Rheumatology Risk factors Skin cancer Statistical analysis Thromboembolism TNF inhibitors Tuberculosis Tumor necrosis factor Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this randomized noninferiority trial involving patients with rheumatoid arthritis, cardiovascular events and cancers occurred more frequently with tofacitinib than with a TNF inhibitor, and noninferiority of tofacitinib with respect to these end points was not established.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2109927